09/04/2015 - 11:23am

AstraZeneca on Thursday announced that the Food and Drug Administration approved Brilinta (ticagrelor) tablets at a 60 mg dose for patients with a history of heart attack beyond the first year.

09/02/2015 - 2:03pm

The collaboration will see them working on a BACE inhibitor program to treat Alzheimer’s disease and developing Amgen’s migraine drugs.

09/02/2015 - 12:09pm

Sandoz on Wednesday introduced rivastigmine transdermal system, a generic version of Exelon Patch1, in the United States.

09/02/2015 - 9:44am

he campaign is being undertaken in partnership with the American Chronic Pain Association, the Pain Community, the U.S. Pain Foundation and the American Academy of Pain Management.

09/01/2015 - 3:08pm

PrescribeMedicare is meant to serve as a tool for patients in 2016 when open enrollment for plan choices begins.

09/01/2015 - 9:46am

The company said the patch is a potential solution for the 73% of migraine sufferers who experience nausea with their migraines. 

08/31/2015 - 3:31pm

The guidance was outlined in a blog post by Janet Woodcock, director of the FDA’s center for drug evaluation and research, and Karen Midthum, director of the FDA’s center for biologics evaluation and research.

08/31/2015 - 12:06pm

With Naurex, Allergan potentially expands its development of mental health treatments, as the acquired company’s focus is on developing therapies for brain and nervous system disorders like depression. 

08/28/2015 - 12:44pm

Alvogen on Wednesday announced that it will acquire a portfolio of four pharmaceutical products in the United States from Pfizer.